tetano
Editor, Senior Moderator
Neurochem Res
. 2023 Mar 23.
doi: 10.1007/s11064-023-03912-0. Online ahead of print.
Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog
Itsuro Kazama[SUP] 1 [/SUP]
Affiliations
Abstract
After recovering from the acute phase of coronavirus disease 2019 (COVID-19), many patients struggle with additional symptoms of long COVID during the chronic phase. Among them, the neuropsychiatric manifestations characterized by a short-term memory loss and inability to concentrate are called "brain fog". Recent studies have revealed the involvement of "chronic neuro-inflammation" in the pathogenesis of brain fog following COVID-19 infection. In the COVID-related brain fog, similarly to neurodegenerative disorders caused by neuro-inflammation, brain leukocytes, such as microglia and lymphocytes, are hyperactivated, suggesting the overexpression of delayed rectifier K[SUP]+[/SUP]-channels (Kv1.3) within the cells. In our previous patch-clamp studies, drugs, such as antihistamines, statins, nonsteroidal anti-inflammatory drugs, antibiotics and anti-hypertensive drugs, suppressed the Kv1.3-channel activity and reduced the production of pro-inflammatory cytokines. Additionally, newer generation antihistamines, antibiotics and corticosteroids strongly stabilize mast cells that directly activate microglia in the brain. Taking such pharmacological properties of these commonly used drugs into account, they may be useful in the treatment of COVID-related brain fog, in which the enhanced innate and adaptive immune responses are responsible for the pathogenesis.
Keywords: Brain fog; Chronic neuro-inflammation; Long COVID (coronavirus disease); Lymphocyte Kv1.3-channels; Mast cell stabilizers.
. 2023 Mar 23.
doi: 10.1007/s11064-023-03912-0. Online ahead of print.
Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog
Itsuro Kazama[SUP] 1 [/SUP]
Affiliations
- PMID: 36952147
- DOI: 10.1007/s11064-023-03912-0
Abstract
After recovering from the acute phase of coronavirus disease 2019 (COVID-19), many patients struggle with additional symptoms of long COVID during the chronic phase. Among them, the neuropsychiatric manifestations characterized by a short-term memory loss and inability to concentrate are called "brain fog". Recent studies have revealed the involvement of "chronic neuro-inflammation" in the pathogenesis of brain fog following COVID-19 infection. In the COVID-related brain fog, similarly to neurodegenerative disorders caused by neuro-inflammation, brain leukocytes, such as microglia and lymphocytes, are hyperactivated, suggesting the overexpression of delayed rectifier K[SUP]+[/SUP]-channels (Kv1.3) within the cells. In our previous patch-clamp studies, drugs, such as antihistamines, statins, nonsteroidal anti-inflammatory drugs, antibiotics and anti-hypertensive drugs, suppressed the Kv1.3-channel activity and reduced the production of pro-inflammatory cytokines. Additionally, newer generation antihistamines, antibiotics and corticosteroids strongly stabilize mast cells that directly activate microglia in the brain. Taking such pharmacological properties of these commonly used drugs into account, they may be useful in the treatment of COVID-related brain fog, in which the enhanced innate and adaptive immune responses are responsible for the pathogenesis.
Keywords: Brain fog; Chronic neuro-inflammation; Long COVID (coronavirus disease); Lymphocyte Kv1.3-channels; Mast cell stabilizers.